Subtype
Gastric Adenocarcinoma
CI-CAN-00005355STADExplore in graph →
137 active trials3 approved drugs22 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005355STADExplore in graph →
Clinical trials
448 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (52)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04535414 | Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers | completed | Phase 2 | 195 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06422403 | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers(VALUE-CHECK) | recruiting | Phase 2 | 360 | National University Hospital, SingaporeOTHER | 1 | Jan 10, 2025 |
| clinicaltrials |
| NCT04162665 | Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer | terminated | Phase 2 | 4 | Washington University School of MedicineOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT03368963 | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | active not recruiting | Phase 1 / Phase 2 | 64 | Emory UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06748352 | Safety and Efficacy of Traction Robot-assisted Endoscopic Submucosal Dissection for Early Gastric Cancer | recruiting | N/A | 50 | Shandong UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05555251 | BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors(CONTRAST) | terminated | Phase 1 / Phase 2 | 18 | BioInvent International ABINDUSTRY | 3 | Dec 16, 2024 | clinicaltrials |
| NCT04319757 | ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | completed | Phase 1 | 12 | Acepodia Biotech, Inc.INDUSTRY | 2 | Dec 5, 2024 | clinicaltrials |
| NCT04602689 | Fibrin Glue After ESD for High Risk Patients of Bleeding | completed | N/A | 134 | Seoul National University HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06690268 | Multimodal Model Predicts Recurrence(FUTURE12) | completed | — | 93 | Qun ZhaoOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06667050 | CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer | active not recruiting | Phase 2 | 58 | West China HospitalOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT05056805 | An Exercise and Nutrition Monitoring Intervention (Pt Pal) for the Improvement of Strength in Patients With Pancreatic or Stomach Cancer Receiving Chemoradiation Therapy Before Surgery, SurgeryStrong Study | withdrawn | N/A | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 26, 2024 | clinicaltrials |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer(PDL1x41BB) | terminated | Phase 1 | 160 | Inhibrx Biosciences, IncINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT06645912 | Effect of High Protein ONS on Older Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy | completed | N/A | 46 | Erzincan Binali Yildirim University Mengucek Gazi Training and Research HospitalOTHER_GOV | 1 | Oct 18, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06646783 | Phase IIT Trial of SNA014 | not yet recruiting | Early Phase 1 | 28 | SmartNuclide BiopharmaINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT04253106 | Liquid Biopsies for the Personalized Management of Patients with Hereditary Diffuse Gastric Cancer(LISA-HDGC) | completed | N/A | 16 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT02891447 | Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04065139 | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study(PIPAC EstoK 01) | completed | Phase 2 | 66 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06572319 | Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens | recruiting | Phase 1 / Phase 2 | 35 | Zhejiang Cancer HospitalOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT03647969 | Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer | completed | Phase 2 | 262 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03852251 | A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma | completed | Phase 1 / Phase 2 | 338 | AkesoINDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT05177133 | Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)(AuspiCiOus) | recruiting | Phase 2 | 25 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT02443324 | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer | completed | Phase 1 | 175 | Eli Lilly and CompanyINDUSTRY | 6 | Jul 31, 2024 | clinicaltrials |
| NCT06496789 | Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer | unknown | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT06492317 | RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer | not yet recruiting | Phase 2 | 20 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03959293 | Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma | unknown | Phase 2 | 107 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06342427 | Stomach Cancer Exosome-based Detection(DESTINEX) | completed | — | 809 | City of Hope Medical CenterOTHER | 2 | Jul 8, 2024 | clinicaltrials |
| NCT06466902 | Evaluation of Intra-operative Photographs for the Assessment of a Proper Lymphadenectomy in Minimally-invasive Gastrectomies for Gastric Cancer (PhotoNodes)(PhotoNodes) | recruiting | — | 326 | Azienda Ospedaliero-Universitaria di ParmaOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06196697 | AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer | recruiting | Phase 2 | 50 | Harbin Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06477562 | Surveillance Endoscopy After Proximal Gastriectomy With Double Tract Reconstruction. | completed | — | 160 | Saint Vincent's Hospital, KoreaOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06454435 | Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer | not yet recruiting | Phase 2 | 158 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT06439550 | Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC | not yet recruiting | Phase 2 | 42 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Jun 3, 2024 | clinicaltrials |
| NCT06250075 | Effects of the Use of Probiotics on the Intestinal Microbiota of Patients With Gastric Cancer(PRONIC-G) | completed | N/A | 88 | Universidade Federal do AmazonasOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT04878783 | Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG | active not recruiting | — | 138 | University of Roma La SapienzaOTHER | 2 | May 9, 2024 | clinicaltrials |
| NCT06389448 | Comparison of pCLE and EB in Gastric Lesion Diagnosis | recruiting | N/A | 366 | Huazhong University of Science and TechnologyOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT03330561 | PRS-343 in HER2-Positive Solid Tumors | completed | Phase 1 | 85 | Pieris Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03650348 | PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors | completed | Phase 1 | 41 | Pieris Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT06362070 | Comparison of Outcomes of Multiple Platforms for Assisted Robotic - Gastrectomy | unknown | N/A | 75 | Azienda Ospedaliera Universitaria Integrata VeronaOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT04604132 | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma(FIDES-03) | terminated | Phase 1 / Phase 2 | 47 | Basilea PharmaceuticaINDUSTRY | 15 | Apr 4, 2024 | clinicaltrials |
| NCT05687617 | Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma. | terminated | Phase 2 | 11 | Laval UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04660760 | Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 2 | 116 | Academic and Community Cancer Research UnitedOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT04768218 | BLI for the Diagnosis of Precancerous Conditions | completed | — | 102 | Instituto Portugues de Oncologia, Francisco Gentil, PortoOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT02830594 | Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer | completed | Phase 2 | 14 | City of Hope Medical CenterOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03990025 | Linked Color Imaging vs White Light Imaging for Detection of Gastric Cancer Precursors | completed | N/A | 90 | Changi General HospitalOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT04074343 | TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma | completed | Phase 1 | 20 | University of California, IrvineOTHER | 1 | Feb 2, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 17, 2025source: clinicaltrials